30.66
-0.06 (-0.20%)
| Previous Close | 30.72 |
| Open | 31.19 |
| Volume | 697,400 |
| Avg. Volume (3M) | 1,924,298 |
| Market Cap | 2,667,281,408 |
| Price / Earnings (Forward) | 100.00 |
| Price / Sales | 42.58 |
| Price / Book | 136.06 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Liquidia Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Findell Capital Management Llc | 30 Sep 2025 | 2,830,000 |
| Opaleye Management Inc. | 30 Sep 2025 | 2,615,000 |
| Caprock Group, Llc | 30 Sep 2025 | 1,632,089 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Needham, 69.60%) | Buy |
| Median | 50.00 (63.08%) | |
| Low | 49.00 (BTIG, 59.82%) | Buy |
| Average | 50.33 (64.16%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 30.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 26 Dec 2025 | 49.00 (59.82%) | Buy | 34.41 |
| 04 Nov 2025 | 49.00 (59.82%) | Buy | 27.91 | |
| HC Wainwright & Co. | 04 Nov 2025 | 50.00 (63.08%) | Buy | 27.91 |
| Needham | 04 Nov 2025 | 52.00 (69.60%) | Buy | 27.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jan 2026 | Announcement | Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update |
| 07 Jan 2026 | Announcement | Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 03 Nov 2025 | Announcement | Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences |
| 03 Nov 2025 | Announcement | Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 27 Oct 2025 | Announcement | Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |